🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Soonmyung Paik

Yonsei University

ORCID: 0000-0001-9688-6480

Also affiliated with Severance Hospital, Theragen

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer”.

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Journal of Clinical Oncology(2024)10.1200/jco.23.02344
N/A
0.646DataRank · unranked
17 citations

Jieling Miao, Lajos Pusztai, Matthew P. Goetz, Priya Rastogi, Patricia A. Ganz +17 more

Clinical Treatment Score Post-5 Years (CTS5) and Late Recurrence Risk in Hormone Receptor–Positive, HER2-Positive Breast Cancer

Journal of the National Comprehensive Cancer Network(2024)10.6004/jnccn.2024.7015
N/A
0.104DataRank · unranked
1 citations

Tanmayi Pai, Yaohua Ma, Zhuo Li, Angelica Gil, Alvaro Moreno‐Aspitia +7 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502
N/A
0DataRank · unranked
16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516
N/A
0DataRank · unranked
0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Digital Commons@Becker (Washington University School of Medicine)(2020)10.17615/6e7v-pv95
N/A
0DataRank · unranked
1 citations

Tracy Lively, John A. Olson, Robert J. Gray, Virginia Kaklamani, Della Makower +26 more

Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression

Nature Cancer(2024)10.1038/s43018-024-00862-6
N/A
0DataRank · unranked
30 citations

Yura Seo, Ifé Akano, Lee Shaashua, Gabriel Cardial Tobias, Jakob M. Hebert +34 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140
N/A
0DataRank · unranked
0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501
N/A
0DataRank · unranked
22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more